

Gabriella Scarlatti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8289909/publications.pdf>

Version: 2024-02-01

131
papers

4,915
citations

101543

36
h-index

106344

65
g-index

145
all docs

145
docs citations

145
times ranked

5242
citing authors

#	ARTICLE	IF	CITATIONS
1	Seasonal Betacoronavirus Antibodies™ Expansion Post-BNT161b2 Vaccination Associates with Reduced SARS-CoV-2 VoC Neutralization. <i>Journal of Clinical Immunology</i> , 2022, 42, 448-458.	3.8	7
2	Dichotomy in Neutralizing Antibody Induction to Peptide-Conjugated Vaccine in Squalene Emulsion Contrast With Aluminum Hydroxide Formulation. <i>Frontiers in Immunology</i> , 2022, 13, 848571.	4.8	1
3	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2022, 7, 44.	6.0	2
4	A Case Study to Dissect Immunity to SARS-CoV-2 in a Neonate Nonhuman Primate Model. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	3
5	Identification of CX3CR1+ mononuclear phagocyte subsets involved in HIV-1 and SIV colorectal transmission. <i>IScience</i> , 2022, 25, 104346.	4.1	4
6	Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1472-1481.	3.6	36
7	Continuous HIV-1 Escape from Autologous Neutralization and Development of Cross-Reactive Antibody Responses Characterizes Slow Disease Progression of Children. <i>Vaccines</i> , 2021, 9, 260.	4.4	2
8	Eliminating postnatal HIV transmission in high incidence areas: need for complementary biomedical interventions. <i>Lancet, The</i> , 2021, 397, 1316-1324.	13.7	22
9	Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. <i>Nature Communications</i> , 2021, 12, 2670.	12.8	297
10	Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2021, 6, 103.	6.0	8
11	Eliminating HIV transmission through breast milk from women taking antiretroviral drugs. <i>BMJ, The</i> , 2021, 374, n1697.	6.0	5
12	HIV vaccines: progress and promise. <i>Journal of the International AIDS Society</i> , 2021, 24, e25828.	3.0	3
13	Mild SARS-CoV-2 Infection After Gene Therapy in a Child With Wiskott-Aldrich Syndrome: A Case Report. <i>Frontiers in Immunology</i> , 2020, 11, 603428.	4.8	8
14	Broadly neutralizing antibodies potently inhibit cell-to-cell transmission of semen leukocyte-derived SHIV162P3. <i>EBioMedicine</i> , 2020, 57, 102842.	6.1	5
15	COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. <i>Journal of Clinical Investigation</i> , 2020, 130, 6366-6378.	8.2	97
16	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. <i>Nature Communications</i> , 2019, 10, 2355.	12.8	116
17	Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1. <i>Frontiers in Immunology</i> , 2019, 10, 1025.	4.8	37
18	Seminal Plasma Exposures Strengthen Vaccine Responses in the Female Reproductive Tract Mucosae. <i>Frontiers in Immunology</i> , 2019, 10, 430.	4.8	1

#	ARTICLE	IF	CITATIONS
19	Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization. <i>Frontiers in Immunology</i> , 2019, 10, 2968.	4.8	44
20	Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 193-205.	1.1	17
21	Immunization with Clinical HIV-1 Env Proteins Induces Broad Antibody Dependent Cellular Cytotoxicityâ€“Mediating Antibodies in a Rabbit Vaccination Model. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 206-217.	1.1	5
22	Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. <i>PLoS ONE</i> , 2018, 13, e0206838.	2.5	25
23	Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers. <i>Cell Reports</i> , 2018, 24, 3324-3338.e5.	6.4	49
24	Editorial: HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies. <i>Frontiers in Immunology</i> , 2018, 9, 297.	4.8	22
25	Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficiency Virus Type 1 Clade C Envelope Vaccine. <i>Human Gene Therapy</i> , 2018, 29, 1011-1028.	2.7	7
26	Regulatory T cell abundance and activation status before and after priming with HIVIS-DNA and boosting with MVA-HIV/rgp140/GLA-AF may impact the magnitude of the vaccine-induced immune responses. <i>Immunobiology</i> , 2018, 223, 792-801.	1.9	1
27	Mother-to-Child Transmission of HIV-1: Role of Receptor Usage and Target Cells. , 2018, , 1368-1376.		0
28	Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 880-888.	1.1	22
29	Modified Vaccinia Virus Ankara Vector Induces Specific Cellular and Humoral Responses in the Female Reproductive Tract, the Main HIV Portal of Entry. <i>Journal of Immunology</i> , 2017, 199, 1923-1932.	0.8	12
30	Recent progress in immuneâ€“based interventions to prevent HIVâ€“1 transmission to children. <i>Journal of the International AIDS Society</i> , 2017, 20, e25038.	3.0	8
31	Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report. <i>Clinical Infectious Diseases</i> , 2016, 64, ciw851.	5.8	3
32	Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. <i>Journal of Virology</i> , 2016, 90, 5315-5328.	3.4	12
33	Dynamics of adaptive and innate immunity inÂpatients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial. <i>Clinical Microbiology and Infection</i> , 2015, 21, 876.e1-876.e4.	6.0	10
34	HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial. <i>PLoS ONE</i> , 2015, 10, e0131748.	2.5	37
35	Beneficial Effects of cART Initiated during Primary and Chronic HIV-1 Infection on Immunoglobulin-Expression of Memory B-Cell Subsets. <i>PLoS ONE</i> , 2015, 10, e0140435.	2.5	11
36	<scp>HIV</scp>â€“1 Infection: The Role of the Gastrointestinal Tract. <i>American Journal of Reproductive Immunology</i> , 2014, 71, 537-542.	1.2	25

#	ARTICLE	IF	CITATIONS
37	Phase I HIV Vaccine Trial to Assess Safety and Immunogenicity of DNA Priming and MVA Boosting in Healthy Mozambican Young Adults. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A192-A192.	1.1	0
38	Microbicide-vaccine Combination Provides Significant Protection against Vaginal SHIV-162P3 Challenge in Cynomolgous Monkeys. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A26-A26.	1.1	0
39	Complexity and Dynamics of HIV-1 Chemokine Receptor Usage in a Multidrug-Resistant Adolescent. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1243-1250.	1.1	4
40	HIV-1 Isolation from Infected Peripheral Blood Mononuclear Cells. <i>Methods in Molecular Biology</i> , 2014, 1087, 187-196.	0.9	3
41	Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms. <i>Journal of Translational Medicine</i> , 2014, 12, 335.	4.4	13
42	Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition. <i>BMC Infectious Diseases</i> , 2014, 14, 472.	2.9	4
43	ADCC Measurements in Rabbits Immunized with HIV-1 Vaccine Candidates. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A243-A243.	1.1	0
44	Intradermal HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A31-A32.	1.1	0
45	HIV-1 of Children with Slow Disease Progression Escapes Autologous Neutralization and Triggers Development of Cross-neutralizing Responses. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A98-A98.	1.1	0
46	Boosting of HIV-1 Neutralizing Antibody Responses by a Distally Related Retroviral Envelope Protein. <i>Journal of Immunology</i> , 2014, 192, 5802-5812.	0.8	4
47	Determination of HIV-1 Co-receptor Usage. <i>Methods in Molecular Biology</i> , 2014, 1087, 197-206.	0.9	1
48	Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate. <i>Journal of Translational Medicine</i> , 2013, 11, 165.	4.4	9
49	R5 HIV-1 envelope attracts dendritic cells to cross the human intestinal epithelium and sample luminal virions via engagement of the CCR5. <i>EMBO Molecular Medicine</i> , 2013, 5, 776-794.	6.9	64
50	A Single Amino-Acid Change in a Highly Conserved Motif of gp41 Elicits HIV-1 Neutralization and Protects Against CD4 Depletion. <i>Clinical Infectious Diseases</i> , 2013, 57, 745-755.	5.8	15
51	B-cell subset alterations and correlated factors in HIV-1 infection. <i>Aids</i> , 2013, 27, 1209-1217.	2.2	66
52	Selected HIV-1 Env Trimeric Formulations Act as Potent Immunogens in a Rabbit Vaccination Model. <i>PLoS ONE</i> , 2013, 8, e74552.	2.5	12
53	Therapeutic DNA Vaccination of Vertically HIV-Infected Children: Report of the First Pediatric Randomised Trial (PEDVAC). <i>PLoS ONE</i> , 2013, 8, e79957.	2.5	21
54	Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques. <i>Vaccines</i> , 2013, 1, 305-327.	4.4	10

#	ARTICLE	IF	CITATIONS
55	HIV-Derived Vectors for Gene Therapy Targeting Dendritic Cells. <i>Advances in Experimental Medicine and Biology</i> , 2012, 762, 239-261.	1.6	4
56	Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization. <i>Retrovirology</i> , 2012, 9, .	2.0	0
57	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II. <i>PLoS ONE</i> , 2012, 7, e36438.	2.5	63
58	Broad-Spectrum Inhibition of HIV-1 by a Monoclonal Antibody Directed against a gp120-Induced Epitope of CD4. <i>PLoS ONE</i> , 2011, 6, e22081.	2.5	6
59	Human immunodeficiency virus type 1 mother-to-child transmission and prevention: successes and controversies. <i>Journal of Internal Medicine</i> , 2011, 270, 561-579.	6.0	17
60	A multiplex calibrated real-time PCR assay for quantitation of DNA of EBV-1 and 2. <i>Journal of Virological Methods</i> , 2011, 178, 98-105.	2.1	13
61	HIV-1 co-receptor usage: influence on mother-to-child transmission and pediatric infection. <i>Journal of Translational Medicine</i> , 2011, 9, S10.	4.4	8
62	Flexible use of CCR5 in the absence of CXCR4 use explains the immune deficiency in HIV-1 infected children. <i>Aids</i> , 2010, 24, 2527-2533.	2.2	9
63	HLA-C is necessary for optimal human immunodeficiency virus type 1 infection of human peripheral blood CD4 lymphocytes. <i>Journal of General Virology</i> , 2010, 91, 235-241.	2.9	5
64	Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41. <i>PLoS Pathogens</i> , 2010, 6, e1001195.	4.7	82
65	Phenotype Variation in Human Immunodeficiency virus Type 1 Transmission and Disease Progression. <i>Disease Markers</i> , 2009, 27, 121-136.	1.3	11
66	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report. <i>PLoS ONE</i> , 2009, 4, e4505.	2.5	109
67	P07-04. HIV-1 evolution in mother to child transmission and pediatric disease progression. <i>Retrovirology</i> , 2009, 6, .	2.0	0
68	P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group. <i>Retrovirology</i> , 2009, 6, .	2.0	1
69	P04-20. Humoral immune response in acute HIV-1 infection. <i>Retrovirology</i> , 2009, 6, .	2.0	1
70	Dendritic cells sample HIV-1 through an intestinal epithelial cell monolayer. <i>Retrovirology</i> , 2009, 6, O4.	2.0	2
71	Impact of host cell variation on the neutralization of HIV-1 in vitro. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 400-407.	3.8	15
72	143 Broad Spectrum Neutralizing Antibodies Against HIV-1 Elicited by Immunizing with Fusion Complexes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, .	2.1	0

#	ARTICLE	IF	CITATIONS
73	Higher Placental Anti-Inflammatory IL-10 Cytokine Expression in HIV-1 Infected Women Receiving Longer Zidovudine Prophylaxis Associated with Nevirapine. <i>Current HIV Research</i> , 2009, 7, 211-217.	0.5	6
74	Unexpected dramatic increase in CD4 ⁺ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations. <i>Journal of Medical Virology</i> , 2008, 80, 937-941.	5.0	9
75	A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. <i>Nature Protocols</i> , 2008, 3, 1240-1248.	12.0	141
76	Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. <i>Virology</i> , 2008, 375, 315-320.	2.4	111
77	Virus phenotype variability during disease progression of HIV-1 infected children. <i>Retrovirology</i> , 2008, 5, O28.	2.0	0
78	Role of R5 phenotypic variation in mother-to-child transmission of HIV-1. <i>Retrovirology</i> , 2008, 5, O2.	2.0	0
79	Lack of viral selection in human immunodeficiency virus type 1 mother-to-child transmission with primary infection during late pregnancy and/or breastfeeding. <i>Journal of General Virology</i> , 2008, 89, 2773-2782.	2.9	9
80	HIV-1 with Multiple CCR5/CXCR4 Chimeric Receptor Use Is Predictive of Immunological Failure in Infected Children. <i>PLoS ONE</i> , 2008, 3, e3292.	2.5	25
81	Biological and Genetic Evolution of HIV Type 1 in Two Siblings with Different Patterns of Disease Progression. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1531-1540.	1.1	9
82	Oral CCR5 inhibitors: will they make it through?. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 451-464.	4.1	8
83	Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1. <i>Perspectives in Medical Virology</i> , 2006, 13, 89-108.	0.1	0
84	Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes. <i>Microbes and Infection</i> , 2006, 8, 1424-1433.	1.9	5
85	Cryptic Nature of a Conserved, CD4-Inducible V3 Loop Neutralization Epitope in the Native Envelope Glycoprotein Oligomer of CCR5-Restricted, but Not CXCR4-Using, Primary Human Immunodeficiency Virus Type 1 Strains. <i>Journal of Virology</i> , 2005, 79, 6957-6968.	3.4	80
86	Fusion Complexes and CD4-independent gp120s for the Induction of HIV-1 Neutralizing Antibodies. <i>Retrovirology</i> , 2005, 2, S121.	2.0	0
87	Low Rate of Mother-to-Child Transmission of HIV-1 After Nevirapine Intervention in a Pilot Public Health Program in Yaoundé, Cameroon. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 274-280.	2.1	56
88	Effects of CCR5-Δ32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children. <i>Aids</i> , 2003, 17, 1631-1638.	2.2	42
89	Structural defects and variations in the HIV-1 nef gene from rapid, slow and non-progressor children. <i>Aids</i> , 2003, 17, 1291-1301.	2.2	39
90	Mother-to-child transmission of HIV: developing integration of healthcare programmes with clinical, social and basic research studies. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2003, 92, 1343-1348.	1.5	1

#	ARTICLE	IF	CITATIONS
91	Effects of CCR5-delta32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis. <i>Aids</i> , 2003, 17, 1631-8.	2.2	19
92	Prognostic Value of the Stromal Cell-Derived Factor 1 β Mutation in Pediatric Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Infectious Diseases</i> , 2002, 185, 696-700.	4.0	34
93	Determination of Coreceptor Usage of Human Immunodeficiency Virus Type 1 from Patient Plasma Samples by Using a Recombinant Phenotypic Assay. <i>Journal of Virology</i> , 2001, 75, 251-259.	3.4	100
94	Cell-to-Cell Contact Results in a Selective Translocation of Maternal Human Immunodeficiency Virus Type 1 Quasispecies across a Trophoblastic Barrier by both Transcytosis and Infection. <i>Journal of Virology</i> , 2001, 75, 4780-4791.	3.4	96
95	Follow-Up of Vertically HIV-1-Infected Long-Surviving Children. <i>AIDS Patient Care and STDs</i> , 2001, 15, 59-65.	2.5	7
96	Length Variation of Glycoprotein 120 V2 Region in Relation to Biological Phenotypes and Coreceptor Usage of Primary HIV Type 1 Isolates. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1405-1414.	1.1	33
97	HIV Type 1 Chemokine Receptor Usage in Mother-to-Child Transmission. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 925-935.	1.1	49
98	Polymorphisms in the MBL2 promoter correlated with risk of HIV-1 vertical transmission and AIDS progression. <i>Genes and Immunity</i> , 2000, 1, 346-348.	4.1	61
99	Prognostic Value of a CCR5 Defective Allele in Pediatric HIV-1 Infection. <i>Molecular Medicine</i> , 2000, 6, 28-36.	4.4	31
100	Enhanced HIV infectivity and changes in GP120 conformation associated with viral incorporation of human leucocyte antigen class I molecules. <i>Aids</i> , 1999, 13, 2033-2042.	2.2	29
101	Selection of Maternal Human Immunodeficiency Virus Type 1 Variants in Human Placenta. <i>Journal of Infectious Diseases</i> , 1999, 179, 44-51.	4.0	73
102	Nonproductive Human Immunodeficiency Virus Type 1 Infection of Human Fetal Astrocytes: Independence from CD4 and Major Chemokine Receptors. <i>Virology</i> , 1999, 264, 370-384.	2.4	113
103	An Unusual HIV Type 1 env Sequence Embedded in a Mosaic Virus from Cameroon: Identification of a New env Clade. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1585-1589.	1.1	24
104	Polymorphism at codon 54 of mannose-binding protein gene influences AIDS progression but not HIV infection in exposed children. <i>Aids</i> , 1999, 13, 863.	2.2	35
105	Chemokines Released by Lipopolysaccharide (LPS)-stimulated Human Macrophages Suppress HIV-1 Infection in Both Macrophages and T Cells. <i>Journal of Experimental Medicine</i> , 1997, 185, 805-816.	8.5	160
106	Antigen-driven Chemokine-mediated HIV-1 Suppression by CD4+ T Cells from Exposed Uninfected Individuals Expressing the Wild-type CCR-5 Allele. <i>Journal of Experimental Medicine</i> , 1997, 186, 455-460.	8.5	116
107	Correlation between HIV sequence evolution, specific immune response and clinical outcome in vertically infected infants. <i>Aids</i> , 1997, 11, 1709-1717.	2.2	31
108	The Role of Virologic and Immunologic Factors in Mother-to-Child Transmission of HIV-1. <i>American Journal of Reproductive Immunology</i> , 1997, 38, 197-200.	1.2	8

#	ARTICLE	IF	CITATIONS
109	In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. <i>Nature Medicine</i> , 1997, 3, 1259-1265.	30.7	595
110	Paediatric HIV infection. <i>Lancet</i> , The, 1996, 348, 863-868.	13.7	98
111	Detection of CD8 T-cell expansions with restricted T-cell receptor V gene usage in infants vertically infected by HIV-1. <i>Aids</i> , 1996, 10, 1621-1626.	2.2	19
112	Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS. <i>Immunology Letters</i> , 1996, 51, 23-28.	2.5	21
113	Mother-to-child transmission of HIV-1. <i>Current Opinion in Infectious Diseases</i> , 1995, 8, 59-65.	3.1	4
114	Biological Phenotypes of HIV-1 in Pathogenesis and Transmission. <i>Antibiotics and Chemotherapy</i> , 1994, 46, 18-24.	0.5	9
115	Peptide serology for analysis of the inter- and intra-individual variation in the HIV-1 V3 domain. <i>Aids</i> , 1994, 8, 413-422.	2.2	10
116	Autologous Neutralizing Antibodies Prevail in HIV-2 but Not in HIV-1 Infection. <i>Virology</i> , 1993, 193, 528-530.	2.4	90
117	Transmission of Human Immunodeficiency Virus Type 1 (HIV-1) from Mother to Child Correlates with Viral Phenotype. <i>Virology</i> , 1993, 197, 624-629.	2.4	138
118	Early detection of IgA specific antibodies in HIV-1 infected children by peptide-ELISA and peptide time-resolved fluoro-immunoassay. <i>European Journal of Pediatrics</i> , 1993, 152, 484-489.	2.7	3
119	Analysis of the HIV-1 Envelope V3-Loop Sequences from Ten Mother-Child Pairs. <i>Annals of the New York Academy of Sciences</i> , 1993, 693, 277-280.	3.8	3
120	Antigen Detection Is a Reliable Method for Evaluating HIV/SIV Neutralization Assays. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 501-504.	1.1	23
121	Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1: Correlation with Neutralizing Antibodies against Primary Isolates. <i>Journal of Infectious Diseases</i> , 1993, 168, 207-210.	4.0	185
122	Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 1721-1725.	7.1	193
123	Epitope Specificity, Antibody-Dependent Cellular Cytotoxicity, and Neutralizing Activity of Antibodies to Human Immunodeficiency Virus Type 1 in Autoimmune MRL/lpr Mice. <i>Journal of Infectious Diseases</i> , 1993, 167, 1267-1273.	4.0	10
124	HIV infection leads to differential expression of T-cell receptor V β 2 genes in CD4+ and CD8+ T cells. <i>Aids</i> , 1993, 7, 633-638.	2.2	45
125	Neutralizing antibodies and viral characteristics in mother-to-child transmission of HIV-1. <i>Aids</i> , 1993, 7, S45-48.	2.2	53
126	Correlation between seroreactivity to HIV-1 V3 loop peptides and male-to-female heterosexual transmission. <i>Aids</i> , 1993, 7, 29-32.	2.2	10

#	ARTICLE	IF	CITATIONS
127	Patterns of Immunoglobulin G Subclass Reactivity to HIV-1 Envelope Peptides in Children Born to HIV-1-Infected Mothers. <i>Aids</i> , 1992, 6, 365-372.	2.2	14
128	Ugandan HIV-1 V3 loop sequences closely related to the U.S./European consensus. <i>Virology</i> , 1992, 190, 674-681.	2.4	41
129	Prognostic significance of immunologic changes in 675 infants perinatally exposed to human immunodeficiency virus. <i>Journal of Pediatrics</i> , 1991, 119, 702-709.	1.8	79
130	Polymerase chain reaction, virus isolation and antigen assay in HIV-1-antibody-positive mothers and their children. <i>Aids</i> , 1991, 5, 1173-1178.	2.2	85
131	Autosomal Dominant Microcephaly Without Mental Retardation. <i>JAMA Pediatrics</i> , 1987, 141, 655.	3.0	13